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The genus Mycobacterium contains many pathogenic bacteria that are known to cause 
serious diseases in humans.  One of the most well-known of these bacteria is Mycobacterium 
tuberculosis, or Mtb, which is the causative agent of tuberculosis. It infects nearly one-third of 
the world’s population and kills 1.4 million people annually.  Another important mycobacterial 
pathogen is Mycobacterium abscessus, or Mabs, which causes respiratory infections in cystic 
fibrosis patients.  One of the biggest difficulties in combating these pathogens is the lack of 
effective diagnostics, as current strategies hold many pitfalls and can be unreliable. One common 
method used is sputum smear microscopy which involves acid fast staining of the bacteria 
present in a patient’s sputum.  This method of detection fails to detect more than 50% of 
infections and is unable to differentiate between species of mycobacterium.  This project 
introduces a novel method of mycobacterial diagnostics using binary deoxyribozymes 
(DNAzymes).  Binary DNAzymes recognize bacteria-specific nucleic acid sequences and bind to 
them, forming a catalytic core which cleaves a substrate molecule.  This cleavage separates a 
quencher molecule from a fluorophore, which results in a fluorescent output.  This flexible assay 
platform has great potential for the detection of Mtb or Mabs.  Our data shows the specificity of 
the DNAzymes allowing for a differential diagnosis of various species of Mycobacteria.  It also 
shows the limit of detection of this technology and its additional utility in molecular typing of 
Mtb clinical isolates as well as drug resistance characterization.  This multipurpose tool can 
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The genus Mycobacterium contains many pathogenic bacteria that are known to cause 
serious diseases in humans.  One of the most well-known of these bacteria is Mycobacterium 
tuberculosis (Mtb), which is the causative agent of tuberculosis (TB).  Mtb infects nearly one-
third of the world’s population and kills 1.4 million people annually [1].  Although Mtb was first 
identified as the causative agent of TB in 1893 by Robert Koch, Mtb-human interactions date 
back to ancient Egypt and even earlier [2, 3]. 
Mtb is an acid-fast staining gram-positive bacillus, due to its cell wall’s ability to take up 
a positively charged dye.  This characteristic is indicative of the molecular structure of the cell 
wall, which is composed primarily of mycolic acid and mycolic acid derivatives [4].  These lipid 
chains vary in size, ranging from 60 to 90 carbons long [5].  The specific lipids may vary 
between different species in the Mycobacterium genus [4].  These long chain fatty acids can 
elicit an immune response in a mouse animal model, indicating their recognition as a PAMP, or 
Pathogen Associated Molecular Pattern, by the host immune system [6].  The mycolic acid along 
with the LPS layers form an envelope which protects the bacteria from host defenses such as 
degradative enzymes by forming a permeability barrier and free radicals via its cycloproponated 
mycolic acid residues [7].   
Mtb is transmitted via aerosolized droplets produced when an infected individual coughs 
and expels the bacteria into the environment.  Transmission is accomplished when the bacteria is 
taken up into a host’s airways and into the lungs where it is internalized by alveolar macrophages 
2 
 
into a phagosome [8].  While in the phagosome the bacteria secrete effector proteins which 
manipulate the phagosome morphology and recruitment of host proteins involved in vesicle 
trafficking.  This prevents fusion of the lysosome, allowing the bacteria to survive within the 
phagosome and avoid both acid exposure and hydrolytic enzymes [9].  In the case of active TB 
disease, which only occurs in 5 – 10% of Mtb infections, the bacteria are able to multiply 
unchecked within the macrophage and eventually cause cell necrosis and tissue damage [10].  It 
is from this point that the bacteria may spread into the capillaries of the lungs and move 
systemically throughout the host.  Transmission is accomplished due to the coughing response to 
the necrosis within the lungs [8].   
The hallmark of a pulmonary TB infection is the presence of a granuloma, a tumor-like 
walled off nodule containing infected macrophages, neutrophils, and dendritic cells [8].  Within 
the granuloma, the Mtb are located within the macrophages directly within the center of the 
granuloma [11].  These infected cells are surrounded by abnormal immune cells such as giant 
multinucleated cells and fat containing “foamy macrophages [12].”  The formation of a 
granuloma may be an innate immune response to prevent transmission, however current theories 
exist that the granuloma formation is evolutionarily beneficial to the bacteria by offering both 
protection and nutrients [13].  Mtb within the granuloma are dormant, replicating infrequently 
and become highly drug resistant via intrinsic biochemical mechanisms such as efflux pumps [8, 
14]. About 90% of those infected with Mtb do not display symptoms immediately and are 
referred to as having a latent TB infection (LTBI).  In a LTBI, Mtb growth is restrained by 
activated macrophages, limiting their ability to spread.  An acute production of T-cells is seen at 
the peripheral lymph nodes, however production of naïve T cells decline during the chronic 
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infection due to inefficient T cell priming [15].  Th1 T-cells produced aid in preventing 
reactivation of the granuloma via the production of cytokines, however research suggest some 
cytokines may activate Mtb dormancy genes [16]. LTBI can remain asymptomatic for years or in 
5-10% of the cases can reactivate to produce a symptomatic disease.  Some research suggests 
now that the recruited neutrophils may play a role in the progression of latent to active Tb 
infection, causing necrotic cell death of the macrophages within the granuloma containing the 
Mtb [8].  This results in caseous necrosis of the granuloma, which facilitates escape and 
transmission of the bacteria and allows the cycle to repeat [8, 14] .     
Mycobacterium abscessus 
Another pathogenic member of the Mycobacterium genus is Mycobacterium abscessus 
(Mabs).  Mabs is a rapidly growing acid-fast gram-positive rod.  Mabs acid-fast properties, 
similar to Mtb, are due to the high concentration of mycolic acid present in its cell wall [4].  
Mabs was first described in 1953 after it was identified from an abscess in a patients knee, and 
was originally classified as a subspecies of M. chelonae [17].  In 1992 genomic analysis and 
hybridization studies allowed the determination that Mabs is sufficiently distinct enough from 
Mycobacterium chelonae to warrant reclassification as a distinct species [18].   
Mabs infections are commonly seen in patients who are immunocompromised.  Mabs has 
therefore been noted as a common cause of hospital borne infections in a patient post-surgery 
[19-21].  Mabs infections can be pulmonary, looking remarkably similar to a Mtb infection [22].  
Patients with cystic fibrosis are at a significantly higher risk of developing a pulmonary infection 
from Mabs than the general public [23].  Studies estimate that 5-12% of all CF patients are 
infected with Mabs, with that number on the rise [22, 24, 25].  Mabs infections can also be 
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extrapulmonary and can occur anywhere on the host, including the eye, with a majority reported 
as subcutaneous [26].  An extrapulmonary Mabs infection can commonly produce an abscess, or 
walled off fluid filled sac, giving Mycobacterium abscessus its namesake [27].  Although 
originally considered rare Mabs infections are now 10 times more common in the USA than Mtb 
infections [19, 28].   
Drug Resistance  
 Treatment of both Mtb and Mabs involve the usage of different multi-drug cocktails 
which are taken for 6-9 months [29, 30].  Mabs is extremely difficult to treat due to intrinsic drug 
resistances to a variety of treatment options, including the drugs used to treat Mtb.  The effects of 
its lipid envelope, degradative enzymes and efflux pumps, result in an even longer antibiotic 
treatment regimen than that for Mtb [31, 32].  Mtb has been shown to express a variety of 
mechanisms to survive drug treatment.  Dormant bacteria may be signaled from a variety of 
stress conditions such as the decrease in pH or hypoxia inside of the phagosome to begin 
transcription of essential genes [33].  This results in the upregulation of multiple efflux pumps 
and drug inactivating enzymes which confer drug resistance to several antibiotic compounds 
such as tetracycline [34-37].  The complex regulons which control these efflux pumps are 
currently new targets of antimicrobial research and development.      
Treatment of Mtb has become increasingly difficult due to the emergence of drug 
resistance mutations in the Mtb genome.  It has been shown that SNP’s, or single nucleotide 
polymorphisms, can alter a drug target and prevent antimicrobials from inhibiting their target’s 
function.  Mtb can acquire multiple drug resistance mutations, resulting in Multi-Drug Resistant 
Tuberculosis (MDR-TB).  A Mtb infection will be diagnosed as MDR-TB if it is shown that the 
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bacteria has resistance to both isoniazid and rifampin, two first line treatment options [38].  
Rifampin (Rif) targets the β subunit of the RNA polymerase, encoded by the rpoB gene [39].  It 
has been shown that the rpoB gene contains an 81 base pair hotspot region which has a 
significantly higher rate of mutations in Rif-resistant strains of Mtb, indicating a genetic target 
for drug-mediated artificial selection [40].  Mutations in both the 526 and 531 codons have 
commonly been shown to confer drug resistance, altering the Rif binding site on the β subunit 
[41].   
 Isoniazid (Inh) is another first line treatment option for Mtb [38].  Isoniazid binds the 
product of the inhA gene, a long-chain enoyl-acyl carrier protein reductase involved in 
elongation of the mycolic acid fatty chains [42, 43].   Mutations in the inhA gene confer 
resistance to Inh by preventing binding in the active site, however the occurrence of a mutation 
in the ORF (open reading frame) is not commonly the case [44-46].  Mutations within the inhA 
promoter also result in resistance due to increased production of the protein product, resulting in 
low-level resistance to clinically used Inh concentrations [47].  Missense mutations in the katG 
gene, a gene which encodes a catalase-peroxidase enzyme, also confer Inh resistance [45, 48-50].  
The KatG protein activates Inh by coupling it to NAD(+)/ NADH, forming an active product.  
Mutations in KatG prevent this activity, however both catalase and peroxidase activity is 
maintained indicating a more complex relationship between KatG and Inh than originally 
hypothesized [49, 51].   
 Extensively drug resistant TB (XDR-TB) is a subtype of MDR-TB where the bacteria are 
additionally resistant to a fluoroquinolone (FQ) as well as an injectable second line drug.  
Fluoroquinolones bind to the gyrase and topoisomerase enzymes used to move the replication 
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fork forward during DNA replication and relieve tension by unwinding the DNA [52].  The 
binding of FQs prevents DNA replication and damages the genome, eliciting an SOS cellular 
response and the generation of oxygen radicals resulting in cell death [53].  Resistance to FQs is 
due to mutations in the gyrA gene or the gyrB gene, both of which encode gyrase enzymes in 
Mtb [54].  These mutations change the amino acid sequence in the FQ binding site, dramatically 
increasing its minimum inhibitory concentration [55].    
Diagnostics and Drug Resistance Characterization 
Before the development of molecular techniques, a pathogenic mycobacterial infection 
was diagnosed based on sputum smear microscopy [56].  This technique is quick and 
inexpensive, which is why it is still currently utilized as a Point of Care (POC) diagnostic.  An 
infected patient is required to provide a sputum sample, which is then processed to isolate the 
bacteria.  The sample is then stained with carbol-fuchsin and counterstained with methylene 
blue.  Due to the mycolic acid component of the cell wall, the carbol-fuchsin will be retained by 
the mycobacterium, resulting in a red appearance.  This method of staining is also referred to as 
the Ziehl-Neelsen stain, and can detect a minimum of 5,000 to 10,000 bacilli per milliliter [57, 
58].  Acid fast staining has been the gold standard for detecting Mtb for over 100 years due to its 
cost effectiveness.  Unfortunately, this technique is highly ineffective at detecting an infection, 
failing to do so almost 50% of the time [59].  Sensitive detection is even more problematic in 
children and patients that are co-infected with HIV [60, 61].    This is likely due to the inability 
to obtain a large enough sputum sample to visualize the bacteria.  Higher occurrences of extra 
pulmonary TB in immunocompromised patients also make diagnostics using sputum more 
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difficult [60].  The Ziehl-Neelsen stain is also unable to differentiate between different species in 
the Mycobacterium genus. 
Another non-molecular method of diagnosing pathogenic mycobacteria is by using an 
apparatus known as a Mycobacteria growth indicator tube (or MGIT).  The MGIT tube contains 
Middlebrook 7H9 Broth, a liquid growth medium containing the essential composition for 
Mycobacterial growth [62].  After a patient’s sputum is processed, the sample is placed in the 
MGIT tube.  If mycobacteria are present then they will begin to grow in the tube and respire 
using the dissolved oxygen.  The depletion of oxygen in the tube results in the activation of a 
fluorescent compound and therefore detection.  The increasing cases of drug resistant Mtb has 
resulted in resistance characterization becoming a necessary and integral part of both treatment 
and diagnostics [63].  Adding various drugs such as Rif and Inh to the MGIT allow this test to be 
utilized for drug susceptibility testing [38]. 
Another common technique used to diagnose Mtb is the Mantoux test, also known as the 
PPD (Purified Protein Derivative) skin test or the Tuberculin skin test.  This test relies on 
analyzing the body’s response to a small injection containing tuberculin, a protein extract from 
Mtb [64].  The actual make-up of PPD may vary and is known to contain many different 
antigens.  After the tuberculin has been injected, the size of the raised skin is measured in 
millimeters.  A positive result indicates the host has already mounted an immune response to Mtb 
or an Mtb like antigen.  The criteria for diagnostics may vary between patients, with specific size 
intervals and additional risk factors of the patient contributing to the analysis [64].  A chest X-
ray usually follows to determine if an active disease state is present.   
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The PPD skin test, which does not indicate an active infection but only the presence of a 
secondary immune response, is known to cross react with patients who have previously been 
vaccinated with the BCG vaccine.  The BCG, or Bacille de Calmette et Guérin, vaccine is made 
of an attenuated strain of Mycobacterium bovis, a mycobacterium which causes TB-like 
symptoms in cattle.  Mycobacterium bovis contains enough similarities with Mtb to elicit an 
immune response, however the efficacy of the vaccine is anywhere from 0 – 80%, which is why 
the vaccine is not widely utilized in the United States (however it is used widely around other 
parts of the world) [65].  Due to the antigenic similarities between Tuberculin and the BCG 
vaccine, those previously vaccinated will elicit a more powerful immune response, resulting in a 
false positive.  False positives may also result from an infection by other members of the 
Mycobacterium genus, such as those found in the environment [66, 67].   
Modern molecular biology has opened the door for new methods of diagnostics of 
pathogenic mycobacteria.  Nucleic Acid Amplification Tests (or NAATs), rely on the usage of 
polymerase chain reaction (PCR) to amplify specific sequences of DNA derived from the 
bacteria [68].  Common targets for identification of the bacteria are the highly conserved and 
species specific 16S and 23S rRNA of the ribosome [69].  The amplicon may then be sequenced 
for diagnosis or hybridized to a molecular probe [70].  A hybridization probe is a synthetic 
oligonucleotide containing a sequence that is complimentary to the target sequence.  Binding of 
the molecular beacon may separate a fluorophore from a quencher molecule, resulting in a 
fluorescent signal.  By targeting the genes responsible for drug resistances, molecular probes are 
also able to characterize the drug resistances of the bacteria [71].  This can also be determined 
via DNA sequencing.  New advancement in molecular diagnostics has allowed the process to be 
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miniaturized by using oligonucleotides covalently linked to a membrane or a microchip [72].  
This technique is highly effective and only requires a small amount of DNA.   
A commercially available diagnostics technique that implements NAATs is the Cepheid 
Gene Xpert which can both detect Mtb and Rif drug resistance.  The WHO has financed 
promotion of the Gene Xpert, subsidizing the costs of the instrument and assay reagents in 
resource poor countries with high endemic TB rates.  This technology takes two hours to both 
analyze the presence of Mtb and characterize Rif drug resistance [73, 74].  Unprocessed sputum 
is sonicated to lyse the bacteria and the nucleic acid is purified and concentrated.  The nucleic 
acid is then PCR amplified and hybridized to probes which provide species identification along 
with probes which target the rpoB gene.  Gene Xpert’s sensitivity was determined via a LOD 
study to be 131 CFU per ml and can accurately differentiate against non-tuberculosis 
mycobacteria by targeting nonhomologous regions of the rpoB gene [73].  The rpoB gene is 
targeted by 5 separate molecular beacons, each requiring their own unique color to both diagnose 
and characterize Mtb [75].  Unfortunately it seems this technology has only proved cost effective 
in reference centers, requiring expensive equipment and reagents.  The requirement of electricity 
and trained personnel makes this technique difficult to implement into a Point of Care diagnostic 
setting [76].   
Mtb Genetic Diversity and Classification 
Molecular tools for genetic characterization of Mtb revealed lineage specific differences, 
allowing populations to be sub-classified into both lineages and strains [77].  The Mtb lineages 
can be classified as either modern or ancient, with lineages 2-4 considered modern.  This 
classification is based on the presence or absence of TbD1, which is absent in modern strains 
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[78].   There are 7 Mtb lineages that can infect humans, each of which are associated with 
different geographical regions (see table 1).  The seven lineages can be further divided into 
different strains, each of which has a unique genetic makeup.  The two strains of Mtb that are 
most common in research lab settings are H37Rv and CDC1551.   
Table 1: Mtb Lineages 
Because the different strains are over 90% 
genetically identical, it was originally believed that 
there were no significant differences between them. 
Recent evidence however suggests that the different 
Mtb lineages differ in virulence [77].  Unlike many 
other pathogenic bacteria, Mtb does not possess any 
toxin mechanisms; therefore virulence is often directly 
equated to transmission.  It has also been seen that a 
lower immunological response is correlated to higher 
bacterial populations in the host, resulting in higher transmission[77].  Modern strains are 
commonly associated with a delayed inflammatory response and are therefore seen to exhibit a 
higher level of transmission along with differences in global gene expression and macrophage 
survival [79, 80].  These modern lineages are also associated with a higher likelihood of 
progression to an active disease state and are seen more globally than the ancient strains, 
suggesting that the delayed inflammatory response may be associated for the globalization of the 
lineages.  Between the modern lineages, lineage 2 is seen to have the highest virulence along 
with the highest occurrences of de novo drug resistances [81].  Ford et al. have shown that this 
Lineage Geographic Classification 
1 Indo-Oceanic 
2 East-Asian 
3 East- African – Indian 
4 Euro-American 
5 West- Africa 




may be a result of the higher mutation rate seen within lineage 2 [82].  These phenotypic 
differences illustrate the effect in both the disease progression and treatment that the Mtb’s 
genetic variability has on an infection.   
Mtb lineage and strain identification is useful to track Mtb’s virulence, evolution, and for 
epidemiological studies [83, 84].  The spread of Mtb can be mapped out according to lineage, 
allowing determination of population based infection patterns.  Analysis of the Mtb genome in 
seals suggests a similarity between the murine strain and the strains seen in the Americas, 
suggesting that Mtb may have jumped from seals to humans [85].  On a micro-population basis, 
analysis of the different lineages and strains can elucidate infection patterns allowing the 
determination of transmission of Mtb between individual patients.  It is also useful in the 
determination of nosocomial infections along with the origin of MDR/XDR-TB, allowing 
researchers to analyze whether a patient infected with Mtb acquired the infection within the 
hospital or before entering it [86].  Finally, strain typing can be used in conjunction with drug 
resistance determination in order to determine the prevalence of de novo mutations conferring 
drug resistance.  This can be used to help determine if drug resistant Mtb strains in health-care 
settings are due to internal transmission of the MDR-TB or due to evolution of resistance during 
treatment selection.   
Strain Typing Methods  
A variety of molecular techniques have been used to classify and type Mtb, analyzing 
genetic markers such as SNPs, insertions, repeats and deletions.  The first molecular technique 
used to analyze Mtb was restriction fragment length polymorphism (RFLP) typing.  This 
technique relies on a difference in copy numbers and location of a genomic insertion sequence 
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(IS6110) in the Mtb genome and was originally hailed as the “gold standard” of strain typing 
[87].  RFLP involves the digestion of the chromosomal DNA with an endonuclease, resulting in 
the production of many fragments of variable lengths.  The digested DNA is then separated on an 
agarose gel via electrophoresis, where DNA fragments of larger sizes migrate slower than those 
of smaller sizes.  The gel is then blotted onto a nylon membrane which absorbs the DNA and 
retains their relative positioning on the gel.  The IS6110 insertion sequence is then detected using 
fluorescent or radioactive probes and imaged.  This allows for determination of repeat sequences 
relative to the migration pattern of the DNA band and therefore characterization of the strains 
[88, 89].  Unfortunately this technique requires large amount of DNA and has a propensity of 
contamination, illustrating the need of newer technology. 
Only a few years later, the need for more effective molecular techniques led the way to 
PCR-based methods of analysis being developed.  By utilizing primers specific to sequences 
found only in Mtb, the specificity of the PCR based characterization methods were determined to 
be 100% [77].  Two methods of PCR based analysis that have become common in strain 
identification include Spoligotyping and MIRU typing.  Spoligotyping, or spacer oligotyping, 
involves PCR amplification of 43 unique regions located between direct repeats in the Clustered 
Regularly Interspaced Short Palindromic Repeat region (CRISPRs) [90].   This results in the 
amplification of a large number of fragments which may vary in size.  The amplified fragments 
are then hybridized to a membrane which has the corresponding oligonucleotides covalently 
bonded.  The hybridization pattern differs from each lineage and strain of Mtb, allowing for 
effective strain identification [88].  This technique can be used in conjunction with RFLP typing 
or independently [91]. 
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MIRU typing differs from spoligotyping in the target of the PCR amplification.  MIRU 
typing is accomplished via the PCR amplification of MIRUs, or Mycobacterial Interspersed 
Repetitive Units [92].  These MIRU’s are found within the Mtb genome and are reminiscent of 
human Variable Number Tandem Repeats (VNTRs) [93].  The MIRUs of interest are amplified 
via PCR and separated using gel electrophoresis.  The gel is then stained and the size of the band 
is determined via comparison to a molecular marker of known sizes [89].  Results from both 
MIRU typing and Spoligotyping can be compared to a known culture or compared to an online 
database, allowing for strain and lineage determination [94, 95].  Unfortunately, identical 
patterns between strains can result from convergent evolution which would make strain 
identification and evolutionary determination nearly impossible [96].   
Another method of characterization of the Mtb strains and lineage is the determination of 
Large Sequence Polymorphisms (LSPs), also referred to as Regions of Difference (RDs).  This 
method of characterization relies on amplification of a region of the Mtb genome containing a 
large deletion, followed by gel electrophoresis and detection using probe hybridization [97].  
Because large genomic deletions are irreversible, LSP analysis is very useful for determination 
of a lineages evolutionary history [98]. 
Spoligotyping, MIRU typing and LSP analysis have revealed a high level of variability 
within lineages and strains of Mtb, along with similarities between strains and lineages which 
may have resulted from independent evolutionary events.  This has resulted in the use of whole 
genome sequencing in determining the phylogenetic lineage of an Mtb strain [99, 100].  Whole 
genome sequencing was first accomplished via the shotgun sequencing method, where the entire 
genome is randomly cleaved and each fragment in inserted into a plasmid and transformed into 
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competent cells.  The individual fragments were then sequenced and assembled using a variety 
of computer programs [101].  Whole genome analysis not only showed LSP but also elucidated a 
variety of important SNPs, or single nucleotide polymorphisms.  These SNPs are differences in a 
single nucleotide between lineages or strains of Mtb [102, 103].  Recently an algorithm has been 
developed which allows lineage determination based on the sequencing of only a few genes, 
relying totally on the determination of a few SNPs in order to classify a strain of Mtb [104]. 
Binary Deoxyribozymes 
One form of molecular diagnostics and characterization that has not been applied to Mtb 
or Mabs before is a binary deoxyribozyme, or DNAzyme.  DNAzymes are catalytic strands of 
DNA based on naturally occurring ribozymes which, in the presence of a metal cofactor, have 
been shown to facilitate the cleavage of an RNA or RNA/DNA phosphodiester bond [105].  
Variations exist however which have peroxidase like activity or silence genes via mRNA 
cleavage [106, 107].  One of the most studied DNAzymes is the 10-23 DNAzyme which cleaves 
an RNA molecule between a purine and pyrimidine [108].  The region of the DNAzyme which is 
enzymatically active is referred to as the catalytic core (see Figure 1a).  The deoxyribozyme was 
first developed by Breaker and Joyce after selective amplification of random nucleotides [109, 
110].  The use of a peptide bound oligonucleotide allowed for the in vitro selection of 
catalytically active DNA sequences [111].   
UCF professor and collaborator Dr. Dmitry Kolpashchikov, as well as others, have 
shown that a variety of modifications can transform the DNAzyme into an assay which can 
detect the presence of specific nucleic acid sequences.  By splitting the catalytic core of a 
deoxyribozyme, the DNAzyme loses its catalytic activity. However reformation of the core 
15 
 
between the two strands can restore the molecules enzymatic abilities (see Figure 1b) [112, 113].  
The DNAzyme can also be altered so that the transition from inactive to active state only occurs 
in the presence of a specific analyte sequence. The DNAzyme can then cleave a substrate 
molecule, which may vary for fluorescent (see figure 1c) or visual output. This reaction can be 
measured by a plate reader or spectrophotometer [114, 115].  Astonishingly, the binary 
DNAzyme assay has been shown to be specific enough to differentiate between two targets that 
differ by only a single SNP [116, 117].  
 
Figure 1: Development of the Binary Deoxyribozyme.  1a) A standard Deoxyribozyme consists of a catalytic core 
and substrate binding arms.  1b) a Binary Deoxyribozyme consists of 2 separate strands each with analyte binding 
arms complimentary to a target sequence.  1c) When bound to a target analyte, the catalytic core is able to be 
reformed, allowing binding of the substrate binding arms and cleavage of a substrate molecule to release a florescent 
output. 
Designing a binary DNAzyme sensor assay first requires basic knowledge of the binary 
DNAzyme structure.  A fully assembled binary DNAzyme consists of three primary structures, 
the analyte binding arms, the catalytic core, and the substrate binding arms [116].  Each sensor 
strand therefore contains one analyte binding arm, one substrate binding arm and one half of the 
catalytic core (see figure 2).   
The substrate binding arm sequence is designed to be complimentary to the sequence of 
the substrate molecule.  The substrate molecule for the fluorescent assay is a synthetic DNA-
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RNA hybrid oligonucleotide analyte, containing a ribonucleotide directly in the center of the 
molecule allowing for cleavage [114].  Other modifications include a fluorophore and a quencher 
at the 5’ and 3’ of the molecule respectively [114].  The specific substrate utilized is known as 
Mzf Substrate and consists of a FAM fluorophore and BHQ quencher.   
The catalytic core of the DNAzyme is responsible for facilitating the actual enzymatic 
reaction the molecule catalyzes.  Variants of the sequence of the catalytic core exist, resulting in 
a higher or lower catalytic rate [105].  The use of different catalytic cores also alters the chemical 
reactions that the DNAzyme can perform such as bond cleavage or peroxidase-like activity 
[118].   
Similar to the design of the substrate binding arm, the analyte binding arm is designed to 
be complimentary to the target sequence being analyzed, such as sequences found in the rRNA 
of Mtb [119].  Designing these arms requires previous knowledge of the sequence being 
analyzed, and it is these arms which are redesigned to create a new binary DNAzyme assay.   
In a fluorescent binary DNAzyme assay, the complementarity of the analyte and the 
analyte binding arms results in both strands hybridizing to the analyte.  This consequently leads 
to the reformation of the catalytic core and allows the substrate binding arms to bind to the 
substrate molecule.  The newly functional binary DNAzyme then catalyzes the cleavage of the 
substrate molecule which separates the fluorophore and the quencher.  This liberated fluorophore 
can be quantified as fluorescent units using a plate reader or spectrophotometer.  The full 




Figure 2: Structure of a Binary DNAzyme.  All binary DNAzymes consist of substrate binding arms which have a 
complimentary sequence to the substrate molecule, a catalytic core which catalyzes cleavage of the substrate 
molecule, and analyte binding arms which are complimentary in sequence to a target analyte.  Designing a new 
sensor pair only requires redesigning the analyte binding arms.   
The binary DNAzyme has many advantages over conventional molecular diagnostic 
techniques.  Because substrate molecule is universal between all fluorescent DNAzyme assays, 
designing a new assay does not require redesigning or reordering the substrate molecule.  
Altering the probes for a totally new assay simply requires redesigning the two strands which 
bind to the new target analyte [120].  These sensors have been implemented in the detection of 
bacterial nucleic acids, however they can be redesigned to detect other nucleic acid based 
infectious agents such as viruses [120].  Furthermore, detection of human SNPs with binary 
DNAzymes is also possible [121].  Some other advantages of the DNAzyme sensor assay are 
that they do not require trained personnel, and lack the requirement of an amplification step 




Methods and Materials 
Binary DNAzyme Assay 
General Binary DNAzyme Assay 
After designing a binary DNAzyme, the sensors are tested with a matched and 
mismatched analyte to assure their correct design.  Each fluorescent assay also has two intrinsic 
controls built in to analyze both stability of the substrate molecule and the background signal 
produced from unbound sensor strands.  The first control consists of 200nM of the Mzf substrate 
molecule in Col buffer.  Col buffer consists of 50Mm HEPES, 50mM MgCl2, 20mM KCl, 
120mM NaCl, 0.03% Triton X-100 and 1% DMSO.  This buffer supplies the DNAzyme with all 
the essential cations required for catalytic function.  Correct concentration of both the substrate 
and ions within the Col buffer is insured by utilizing 30μl of a 2X Col buffer, adding the 
substrate molecule, and diluting the sample with dH2O up to the standard total reaction volume 
of 60μl.   
Next, a master mix is made consisting of the two sensor strands, substrate, Col 2X buffer, 
and dH2O.  Total volume necessary for each test sample along with a background sample and 
one additional sample is first determined (ReactionVolTotal).  The master mix consists of Col 2X 
buffer at a volume of one half this total reaction volume (ReactionVolTotal /2).  Each sensor strand 
is then added to the master mix at a concentration of 15nM along with the substrate molecule at a 
concentration of 200nM.  To determine dH2O added to the master mix, the total volume is 
multiplied by .75 to give the total master mix volume (MasterMixVol = .75 x ReactionVolTotal).  
dH2O is then added to the master mix to bring to total volume up to this calculated value.   
19 
 
Each sample tube then receives 45μl of the Master mix.  15μl of dH2O is added to the 
background tube, forming the second internal standard for comparison.  The sample tubes 
receive the matched or mismatched analyte at a concentration of 1nM and dH2O is then added to 
bring the total volume of the tubes up to 60μl.   
The samples along with both the substrate and background control are placed in a 384 
well black bottom plate and incubated at 54°C for 1 hour in a hybridization oven.  The 
fluorescent intensity is then measured in a Synergy 4 Biotek Plate Reader.  Detection using the 
plate reader has been optimized, with best results using Filter Based detection with excitation 
and emission wavelengths of 485nm and 520nm respectively and a read height of 1mm.  Each 
fluorescent signal is then divided by the signal of the background control, allowing the 
measurements to be interpreted as a signal to background ratio (S/B).   
Specificity and Limit of Detection 
Assays were designed for Mabs with comparable TB sensors being tested by other 
members of the lab.  Two varieties of the standard binary DNAzyme assay include a specificity 
study along with a limit of detection study.  The goal of the specificity study goal is to compare 
the signal to background ratio obtained by the matched analyte with that of the mismatched 
analyte in the form of a specificity value.  Three different types of analyte were routinely tested: 
synthetic oligonucleotides, total RNA, and PCR amplicons.  1nM of synthetic analyte is utilized 
while 200ng of total RNA is used.  PCR amplicon concentration is difficult to determine without 
purifying out any residual dNTPs, so 15μl of the PCR product is routinely utilized.  When testing 
total RNA as analyte, an additional binary DNAzyme assay is commonly performed using 
sensors complimentary for the sequence of the mismatched analyte to assure integrity of the 
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RNA.  The specificity study is performed in triplicate in order to generate averages along with 
standard deviation.   
The limit of detection (LOD) study utilizes many samples of serial dilution of matched 
analyte in order to form a linear graph which correlates S/B ratios with target analyte 
concentration.  The target analyte is serial diluted in regular intervals to produce many samples 
of decreasing concentration.  A DNAzyme assay is then performed in triplicate on the various 
analyte samples, and a scatterplot is generated comparing S/B ratio (Y) with analyte 
concentration (X).  The LOD value is the concentration of analyte which produces a signal to 
background ratio equal to that of the background sample (no analyte) plus three times the 
background samples standard deviation [122].  The LOD test can be performed on both synthetic 
analytes as well as RNA. 
Visual Identification 
Visual detection is accomplished using a second DNAzyme, known as IPDZ, as the 
substrate molecule in what is known as a DNAzyme cascade [118].  The binary DNAzyme 
facilitates cleavage of a ribonucleotide separating an inhibitory component of the second 
DNAzyme, liberating the catalytic PDz fragment [123]. This DNAzyme folds into a G-
Quadruplex formation and, in the presence of a hemin cofactor, has peroxidase activity which 
can be detected via the oxidation of the colorimetric substrate DAB in the presence of H2O2 (see 
figure 4).  The resulting molecule changes the solution from clear to brown, allowing visual 




Figure 3: Visual Reaction Cascade.  A) A visual binary DNAzyme assay requires the two binary DNAzyme 
strands, each consisting of an analyte binding arm, substrate binding arm, and half of a catalytic core.  The assay 
also requires an inhibited peroxidase like DNAzyme (IPDz).  B) In the presence of a specific analyte, the binary 
DNAzyme is able to bind and reform the catalytic core, allowing cleavage of the inhibitory fragment from the IPDz 
to form PDz.  C) Liberated PDz adopts a G-quadruplex like structure and in the presence of hemin can catalyze an 
oxidoreductive reaction to produce a colored product.   
A visual binary DNAzyme assay consists of the same setup and controls as a fluorescent 
binary DNAzyme assay with a few minor alterations.  The initial substrate molecule, IPDZ, is 
used at a 1μM concentration while each sensor strand is used at 100nM.  The assay is then 
incubated at 50°C for 1 hour.  Afterwards, 2μl of a 1:1 mixture of DAB and hemin at 25μM is 
added to each tube followed by 1μl of H2O2.  After 30 minutes of incubation at room temperature 
the absorbance is measured at 500nm in a spectrophotometer.  Specificity tests were 
accomplished utilizing 100nM of analyte. 
SNP Analysis 
 Specific design parameters must be applied to binary DNAzymes intended for the 
detection of single SNPS.  These sensors are constructed with a long arm and a short arm, with 
the short arm containing the discriminatory SNP.  This methodology allows the strand containing 
the long arm to be utilized for both detection of both wild type and mutant variations.  Because 
the SNP-containing arm is shorter than the nondiscriminatory arm its lower annealing 
temperature allows for more sensitive mismatch discrimination [117].     
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Our approach to DNAzyme-based SNP detection uses an algorithm for strain typing 
developed by Homolka et al. that defined the minimal number of SNPs required for high 
resolution lineage assignment identification (see figure 3) [104].  As proof-of-principle for the 
utility of our technology for strain typing we designed sensors to analyze the GC mutation of 
the 455
th
 residue of the Rv0557 gene which allows the determination of Haarlem vs. 
NonHaarlem lineage (See appendix).  
 
Figure 4: Strain Typing SNPs.  Homolka et al. were able to determine the minimum number of SNPs needed to be 
sequenced in order to effectively characterize strain lineage.  This was accomplished computationally after multiple 
rounds of whole genome sequencing on different strains of Mtb.   
 As a proof of principle experiment to characterize drug resistance, we also designed 
sensors to detect the most common drug resistance mutations within the rpoB gene, a C526G 




 Analysis of SNPs in genes which are present in low copy number requires PCR 
amplification in order for efficient detection.  PCR amplification of a target sequence requires 
two primers which bind both upstream and downstream to the target sequence respectively.  The 
sequence of the forward primer is identical the sense strand while the reverse primer is the 
reverse complement.  A standard PCR reaction includes 1μl DNA at approximately 20ng/μl 
concentration, 1μl each forward and reverse primers at 100ng/μl concentration, .25μl of Phusion 
DNA polymerase at 2000U/ml concentration, 5μl of HF Buffer, 16.25μl of dH2O, and .5μl of 
dNTPs at 10mM concentration.  The PCR reaction sample is then placed into a Philisa thermal 
cycler which can quickly cycle through various temperatures, allowing the DNA to denature, the 
primers to anneal to the separated DNA, and the polymerase to extend the primers and form a 
new strand of DNA.  Initially the sample is heated to 98°C for 3 minutes, followed by 50 cycles 
of 98°C for 10 seconds, 67°C for 15 seconds, and 72°C for 10 seconds.   The temperature is then 
held at 72°C for 30 seconds and cooled to room temperature.  In order to determine drug 
resistance, PCR primers were designed and utilized for the rpoB gene in an effort to characterize 
Rif resistance (see appendix). 
 It has been hypothesized that a binary DNAzyme is more sensitive utilizing single 
stranded DNA (ssDNA) and an analyte compared to double stranded DNA due to needing to 
compete with the antisense strand for hybridization.  One method of generating ssDNA is 
asymmetric PCR.  In asymmetric PCR, one primer is decreased in concentration significantly 
(1:40).  This results in exponential increase in DNA during the initial cycles until the limiting 
primer runs out.  After depleting the limiting primer, extension of only the excess primer causes 
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the linear production of ssDNA.  LATE-PCR, OR Linear After The Exponential PCR, accounts 
for the fact that decreasing the concentration of one of the primers decreases the effective 
annealing temperature, leading to ineffective amplification [124].  LATE-PCR addresses this 
problem via altered design of the limiting primer, where it is extended by 2 to 3 nucleotides.  
This raises the effective annealing temperature of the limiting primer, allowing for an increase in 
output [125].  Both LATE-PCR and symmetric PCR primers were designed for the amplification 




Results and Discussion 
Mabs Detection 
Fluorescent Detection 
Fluorescent sensors to detect Mabs were developed which targeted regions of the 23S 
rRNA, 16S rRNA and tmRNA genes [126].  The sequences selected based upon multiple sequence 
alignments were homologous among different strains of Mabs, allowing detection of all strains.  
The regions selected however were variable between different species of Mycobacterium, 
allowing for efficient species differentiation from Mycobacterium tuberculosis complex.  
Because the genes chosen are present in high copy number, PCR amplification was not needed. 
 
Figure 5: Mabs 23S rRNA, tmRNA and 16S rRNA Limit of Detection using Synthetic Analyte.  A) B) and C) 
represent signal to background ratio of fluorescence at various concentrations of synthetic analyte for Mabs 23S 
rRNA, tmRNA and 16S rRNA respectively.  The red line represents limit of detection.  Each graph represents the 
averages of 3 separate experiments. 
  Limit of detection studies were completed in triplicate using both synthetic analyte and 
total RNA using a range of 0.5nM (0.25nM for 23S rRNA) to 0.015625nM for synthetic analyte 
and 100ng to 6.25ng for total RNA.  The red line indicates the S/B Ratio for the limit of 
detection.  The limit of detection using synthetic analyte was determined to be 48.18pM, 
51.76pM and 28.54pM for 16S rRNA, 23S rRNA and tmRNA sensors respectively.  These 
numbers are similar to that of sensors previously designed to detect 16S rRNA and 23S rRNA in 
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analyte concentration used to determine the value is the same, allowing comparison between the 
sensors.   
 
Figure 6: Mabs 23S rRNA, tmRNA and 16S rRNA Limit of Detection using Total RNA.  A) B) and C) 
represent limit of detection studies utilizing total RNA at various concentrations for Mabs 16S rRNA, 23S rRNA 
and tmRNA respectively.  The red line represents the limit of detection.  Each graph represents the average of 3 
independent experiments.   
The limit of detection using total RNA was determined to be 4.34ng, 37.42ng and 
41.07ng for 16S rRNA, 23S rRNA and tmRNA sensors respectively.  The differences in these 
values are not able to indicate differences in quality of the sensors, as the limit of detection using 
RNA is also influenced by the total copy number in the total RNA.  The results of this study 
demonstrate the potential to detect mycobacterial RNA directly without the need for 
amplification. 
In addition to limit of detection, the specificity ratio of the 23S rRNA and tmRNA Mabs 
sensors were determined by comparing the S/B of the perfect match analyte (Mabs) with the 
mismatch analyte (Mtb).  A high specificity ratio assures that the sensors will be able to 
accurately differentiate between different species of Mycobacterium, preventing the possibility 
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Figure 7: Mabs 23S rRNA and tmRNA Specificity using Synthetic Analyte.  A) and B) represent specificity of 
Mabs 23S rRNA and tmRNA sensors respectively.  Sensors were tested in triplicate with synthetic matched (Mabs) 
and mismatched (Mtb) analyte.   
 The specificity ratios of the 23S rRNA and tmRNA sensors using synthetic analyte were 
determined to be 5.69 and 3.46 respectively.  The matched analyte for the 23S rRNA Mabs 
sensors gave a S/B Ratio of 5.69 while the mismatched analyte only produced a signal of 1.04.  
The difference in the specificity ratios between the 23S rRNA and the tmRNA sensors is 
explained by the lower overall signal the matched analyte produced, with a S/B Ratio of 3.46 
compared to 1.25 produced by the mismatched analyte.  These results show that our sensors were 
accurately able to discriminate against different genetic regions between Mabs and Mtb, 
providing the ability to differentiate between the two mycobacteria.   
Visual Detection 
Visual sensors to detect Mabs which target the 23S rRNA, 16S rRNA and tmRNA genes 
were also developed and tested for their limit of detection and specificity ratio.  These sensors 
were easily designed, utilizing the same analyte binding arms and catalytic core portion as the 
fluorescent sensors, and only required altering the substrate binding arms.  In order to quantify 
the color change due to the colorimetric reaction, absorbance was measured at 500nm.  A 































presence of a matched analyte.  The ability to detect this color change by the naked eye is 
necessary for POC diagnostics as it eliminates the need for expensive equipment to analyze the 
results.   
 
Figure 8: Mabs 23S rRNA, tmRNA and 16S rRNA Visual Limit of Detection using Synthetic Analyte.  A) B) 
and C) represent signal to background of absorbance (500nm) using synthetic analyte at various concentrations for 
Mabs 16S rRNA, tmRNA, and 23S rRNA respectively.  Each graph represents the average of 3 separate 
experiments.  Visual detection was also confirmed via a color change.  The red line represents limit of detection. 
Limit of detection studies were completed in triplicate using synthetic analyte at a 
concentration range of 10nM to 16pM.  The limit of detection was determined to be 946pM, 
948pM and 2624pM for 16S rRNA, tmRNA and 23S rRNA visual sensors respectively.  This is 
not surprising, as the limit of detection of visual sensors are commonly seem to be at least ten 
times higher than that of their fluorescent counterpart [123].   
 
Figure 9: Mabs 23S rRNA and tmRNA Visual Sensors Specificity.  A) and B) represent specificity of Mabs 
visual 23S rRNA and 16S rRNA sensors respectively.  Absorbance (500nm) of each sensor was tested 3 
independent times with matched (Mabs) and mismatched (Mtb) synthetic analyte.  The difference in specificity was 
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The specificity ratios were experimentally determined in triplicate using synthetic 
analyte, with the 23S rRNA and 16S rRNA visual sensors scoring a 2.19 and 2.35 respectively.  
The S/B Ratio for the matched analyte of the Mabs 23S rRNA sensors was 2.41 while the S/B 
ratio for the mismatched analyte was 1.10.  The S/B Ratio for the matched analyte of the Mabs 
16S rRNA sensors was 2.00 while the S/B ratio for the mismatched analyte was 0.85.  The S/B 
Ratios of visual sensors are also commonly seen to be lower than that of fluorescent sensors. 
This is due to the lower signal range of visual assay versus fluorescence.  S/B Ratios using a 
matched analyte on a visual sensor’s typically reaches a maximum of about 2.5. 
Amplification  
Symmetric vs. LATE-PCR 
 Analyzing genes present in low copy number requires the use of an application technique.  
We compared traditional (symmetric) PCR to LATE-PCR (asymmetric) in order to determine the 
most efficient amplification technique for using a binary DNAzyme.  LATE-PCR generates 
ssDNA due to decreasing the concentration of an extended limiting primer.  Primers were 
designed to amplify a small fragment of the 23S rRNA gene in Mtb.  The PCR products were 
then run on an agarose gel and stained with Gel Red to image.  The appearance of a second band 
in the LATE-PCR sample indicates the production of ssDNA.  The PCR product was then 




Figure 10: Symmetric vs. LATE-PCR using 23S Mtb rRNA Sensors.  15μl of symmetric PCR and LATE-PCR 
product amplifying a fragment of Mtb 23S rRNA was tested using a Mtb 23S rRNA fluorescent sensor. 
 Surprisingly, the S/B ratio using symmetric PCR compared to LATE-PCR was nearly 
identical, which was contrary to our working hypothesis.  Figure 11 represents the data from a 
single repetition; however the results were replicated with similar results in multiple independent 
experiments.  The reason the generation of ssDNA does not affect the S/B ratio is still unknown, 
although one possible explanation is because the generation of ssDNA is linear, the total 
concentration of amplicon, single and double stranded, is significantly less than that of 
symmetric PCR.  Another explanation could be that due the small size of the amplicon, the 
binary DNAzyme sensors are able to efficiently outcompete the antisense strand from binding to 
the target.  The excess concentration of the sensors may also increase the signal when using a 
PCR amplicon as an analyte.   
Cycle Optimization 
In order to determine optimal cycle number, primers were designed and used to amplify a 
250 base pair fragment of the rpoB gene of wild type Mtb using 30x, 40x, and 50x cycles.  This 
was confirmed using agarose gel electrophoresis.  A binary DNAzyme assay using rpoB wild 



















Figure 11: rpoB Wild Type Sensors on Determining Optimum PCR Cycle Number.  15μl of standard PCR 
product amplifying a fragment of the Mtb rpoB gene at various cycle numbers was tested using wild type rpoB 
sensors. 
 The maximum S/B of 7.82 achieved with 50 cycles led us to select this as the optimum 
cycle number.  Figure 10 indicates a single rep, however further experiments have confirmed our 
findings.   
SNP Analysis 
Strain Typing 
 We next attempted to utilize the ability of binary DNAzyme sensors to detect SNPs for 
molecular strain typing of Mtb.  Based on a SNP-based typing algorithm proposed by Homolka 
et al (2012), we designed sensors to detect the WT and mutant variants of the G455C SNP in the 
gene rv0557 which distinguishes the Haarlem from non-Haarlem lineage.  In this initial proof of 
principle experiment, the two sensor pairs were tested against synthetic analytes representing the 















Figure 12: Haarlem Vs. NonHaarlem Sensor Specificity.  Both Haarlem and NonHaarlem fluorescent sensors 
were tested using their matched and mismatched analyte respectively.  These sensors targeted a GC mutation of 
the 455
th
 nucleotide of the rv0557 gene. 
 Both Haarlem and NonHaarlem sensors showed excellent specificity against synthetic 
analytes, with a specificity ratio of 3.14 and 3.39 in one rep.  These results combined with our 
data showing binary DNAzyme detection of PCR amplicons suggest a PCR-based binary 
DNAzyme assay would be effective for strain typing Mtb from these two distinct lineages. 
Drug Resistance Analysis 
Sensors to detect wild type rpoB gene were developed and tested against wild type and 
mutant analyte.  The sensors designed detect wild type sequence which would indicate 
susceptibility to Rif.  This means that a loss of signal would indicate the presence of a drug 
resistant mutant.  A wild type sensor was chosen because the loss of signal would occur for any 
mutation to the section of the rpoB gene being amplified, as opposed to detecting just one of 



















Figure 13: Specificity of rpoB Sensors using Wild-Type and Mutant Synthetic Analyte.  Specificity was 
determined using both matched (wild type) and mismatched (drug resistant) synthetic analyte.  This was performed 
in triplicate.   
 Using synthetic analyte the wild type sensors showed an acceptable level of specificity, 
with a specificity ratio of 2.67.  The matched analyte resulted in a S/B ratio of 3.33 while a 
mismatched analyte containing the C526G mutation resulted in a signal of 1.25.  Because the 
rpoB gene is present in low copy number, primers were designed to amplify a 250 base pair 
fragment of the gene containing the 81 base pair hot spot region.  The specificity of the wild type 
binary DNAzyme sensors were then determined using the PCR sample produced from both wild 
type and Rif resistant BCG DNA.  This DNA was generated from artificially selecting an rpoB 
mutation in a strand of BCG within the lab, while the sequence was confirmed by independent 

















Figure 14: rpoB Wild-Type Sensor Specificity using PCR Product.  Specificity was determined using rpoB wild 
type sensors after amplification using CDC1551 WT DNA and artificially selected Rif resistant BCG DNA.  This 
was performed in triplicate. 
 The specificity value of the wild type rpoB sensors using PCR product decreased to a 
2.58, still indicating efficient discrimination between drug susceptible and drug resistant 





















With these experiments, we have shown that binary DNAzyme sensors can be designed 
to efficiently detect and characterize different species of pathogenic mycobacterium.  The 
development of visual sensors also results in the generation of an assay which can translate into 
POC diagnostics due to the ease of reading the output.  We are currently testing out other 
peroxidase substrate molecules which can potentially be used instead of DAB and produce an 
even greater absorbance output.  We also plan on testing other methods of detection such as a 
384 well filter bottom plate, allowing the colored substrate molecule to be condensed into the 
well and result in a stronger visual output.  This would also be an alternative to using a plate 
reader, eliminating the need for expensive equipment. 
The characterization of the rpoB gene is vital in determining drug resistance or 
susceptibility towards Rif, a first line drug used to treat Mtb.  Because of the development of 
MDR-Tb and XDR-Tb, it is necessary to design and test sensors which can characterize 
resistance to additional antibiotics including Inh and FQs.  We have currently developed primers 
to amplify regions of the inhA, katG and gyrA genes, which can be combined with the rpoB 
primers in one PCR reaction.  This should allow the generation of a multiplex PCR product 
which can be subjected to multiple binary DNAzyme assays to elucidate drug resistance 
characterization to many different drugs.   
In an effort to eliminate the need for a thermal cycler, we are currently testing isothermal 
amplification techniques such as Loop Mediated Isothermal Amplification (LAMP).  LAMP 
utilizes 6 primers that recognize 6 distinct regions of DNA in a target sequence and results in the 
generation of concatemeric stem loop DNA structures, all linked together with the same target 
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sequence [127].  The elimination of a thermal cycler greatly increases the possibility that an 






 The detection and differentiation of pathogenic mycobacterium is essential in diagnosis 
and treatment of the disease.  Early diagnosis results in higher survival rates among patients, 
however current methods of diagnostics can be unreliable and expensive.  We have shown that 
sensors developed to detect Mabs are able to detect low quantities of total RNA and synthetic 
analyte and are efficiently able to differentiate between Mabs and Mtb.  We also designed 
sensors to detect Mabs with a visual output, eliminating the need for a plate reader and 
successfully advancing the development of a POC diagnostic test for the detection of pathogenic 
mycobacteria.   
 SNP characterization in Mtb allows for the elucidation of a variety of molecular 
characteristics of the individual strain, such as lineage and drug resistance profile.  We were able 
to successfully design sensors which were sensitive enough to differentiate between two strains 
with a single residue difference.  These sensors efficiently discriminate between two different 
lineages of Mtb, allowing for effective strain typing without the need for whole genome 
sequencing.  
 Characterization of drug resistance is of vital importance when treating an Mtb infection, 
and determining drug susceptibility is vital for determining the course of treatment.  We were 
able to show that binary DNAzyme sensors were able to efficiently differentiate between Rif 
susceptible and Rif resistant Mtb.  We also showed that PCR amplification may be necessary in 
characterizing SNPs found in genes which are present in low copy number, and the symmetric 
PCR is effectively able to amplify a large enough quantity of amplicons to reliably detect with 
DNAzyme sensor.  We also showed that a binary DNAzyme sensor is still efficiently able to 
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differentiate between the different SNPs when using PCR amplicons as the analyte. Overall, 
these experiments make ways to facilitate better treatment of TB by providing a novel platform 
for POC detection.  We have shown that the binary DNAzyme platform is a promising 














Substrate: MzF 5’- AAGGTT-FAM-TCCTCguCCCTGGGCA-BHQ 
 
Sensor Adaptor Strand A Adaptor Strand B (WT specific) 
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5’-CCG GAT AGG ACC ACA CAC TTC ATG GTG AGT GGT GCA AAG CTT TTG 
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Haarlem_455_C 5’- CCACTTGCATCCCCTGGCTGACCGCACTCTGGCGCCGTCCACAGCGAC 
 
Sensor Adaptor Strand A Adaptor Strand B 
Rv0557 Non-
Haarlem Sensor 
















Substrate: IPDZ 5‘- GGG TAG GGC GGG TTG GGT TC rG rU CC ATG AGC AACTCG CCC 
 
Sensor Adaptor Strand A Adaptor Strand B 
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Locus Primer Sequence 
rpoB rpoB_sym200_F 5’- GTCGCCGCGATCAAGGAGTT 




Locus Primer Sequence 
23S rRNA Mtb TB23S_aPCR_F 5’- GAACTCGGCAAAATGCCCCCGTAA 
Tb23s_aPCR_R (For 
LATE-PCR) 
5’- TTCGTGCAGGTCGGAACTTACCCCGACAAGG  
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